2025 Q3 -tulosraportti
57 päivää sittenTarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·30.12.2025Fascinating case with Genmab right now. It's a completely wild multiple contraction🤯 The key figures are rock solid: P/E down to 10.4, from previous highs of 125, and a net margin of a full 56%! Looks like a bargain. But why is it so "cheap"? The reason: The market is pricing in significant risk related to the patent dispute surrounding the blockbuster Darzalex (multiple myeloma, which accounts for approx 70% of revenues). Investors fear a large drop in revenue when the patents expire around 2031. The future hope: Their new, promising cancer drug Epkinly against lymphoma. Sales were $211m in Q1 2025 (approx. 12% of total revenues), and it is central to filling the revenue gap.
·30.12.2025I had Acasunlimab at 100 price points in my spreadsheet. They are gone now. Remember your own considerations. Happy New Year
·30.12.2025Is there anything to suggest that they will deliver a better financial report than the market already expects? It is largely the acquisition of merus that should have the attention here and now, isn't it? Isn't the acquisition completed in Q1? And in that regard, could something emerge that only sees the light of day after closing?
·30.12.2025Is there anything to gain here in the short term or is it better to wait to enter? Someone who is well-versed in the case, thanks in advance.
·30.12.2025I think it will fall as it did 3 months ago, maybe not quite as sharply. My bet is we will go down and test 1900, but I have nothing but a gut feeling to back it up.·30.12.2025The reason I sold out was that we reached and tested the same level as 3 months ago. So I thought it would probably take a dip down again.- ·29.12.2025 · MuokattuAcasunlimab is being scrapped. It doesn't come as the world's biggest surprise, considering the entire process, and it became even more likely with the acquisition of Petos. We are still awaiting clarification on GEN1042. Winkel, however, is left somewhat exposed by now, if 1042 also fails and Epco turns out to be the only success from the "own-pipeline" which was otherwise mentioned as promising. Well. Epco itself might be enough to create long-term profit, with Winkel having spoken warmly about there being gold hidden in the books, and that was apparently also mentioned after Epco was manifested.
- ·23.12.2025How long will one have to wait for approval and isn't it overwhelmingly likely that the approval will come?·23.12.2025Does Genmab have any active applications?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
57 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·30.12.2025Fascinating case with Genmab right now. It's a completely wild multiple contraction🤯 The key figures are rock solid: P/E down to 10.4, from previous highs of 125, and a net margin of a full 56%! Looks like a bargain. But why is it so "cheap"? The reason: The market is pricing in significant risk related to the patent dispute surrounding the blockbuster Darzalex (multiple myeloma, which accounts for approx 70% of revenues). Investors fear a large drop in revenue when the patents expire around 2031. The future hope: Their new, promising cancer drug Epkinly against lymphoma. Sales were $211m in Q1 2025 (approx. 12% of total revenues), and it is central to filling the revenue gap.
- ·30.12.2025I had Acasunlimab at 100 price points in my spreadsheet. They are gone now. Remember your own considerations. Happy New Year·30.12.2025Is there anything to suggest that they will deliver a better financial report than the market already expects? It is largely the acquisition of merus that should have the attention here and now, isn't it? Isn't the acquisition completed in Q1? And in that regard, could something emerge that only sees the light of day after closing?
- ·30.12.2025Is there anything to gain here in the short term or is it better to wait to enter? Someone who is well-versed in the case, thanks in advance.·30.12.2025I think it will fall as it did 3 months ago, maybe not quite as sharply. My bet is we will go down and test 1900, but I have nothing but a gut feeling to back it up.·30.12.2025The reason I sold out was that we reached and tested the same level as 3 months ago. So I thought it would probably take a dip down again.
- ·29.12.2025 · MuokattuAcasunlimab is being scrapped. It doesn't come as the world's biggest surprise, considering the entire process, and it became even more likely with the acquisition of Petos. We are still awaiting clarification on GEN1042. Winkel, however, is left somewhat exposed by now, if 1042 also fails and Epco turns out to be the only success from the "own-pipeline" which was otherwise mentioned as promising. Well. Epco itself might be enough to create long-term profit, with Winkel having spoken warmly about there being gold hidden in the books, and that was apparently also mentioned after Epco was manifested.
- ·23.12.2025How long will one have to wait for approval and isn't it overwhelmingly likely that the approval will come?·23.12.2025Does Genmab have any active applications?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
57 päivää sittenUutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 12.2.2025 | |
| 2024 Q3 -tulosraportti | 6.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·30.12.2025Fascinating case with Genmab right now. It's a completely wild multiple contraction🤯 The key figures are rock solid: P/E down to 10.4, from previous highs of 125, and a net margin of a full 56%! Looks like a bargain. But why is it so "cheap"? The reason: The market is pricing in significant risk related to the patent dispute surrounding the blockbuster Darzalex (multiple myeloma, which accounts for approx 70% of revenues). Investors fear a large drop in revenue when the patents expire around 2031. The future hope: Their new, promising cancer drug Epkinly against lymphoma. Sales were $211m in Q1 2025 (approx. 12% of total revenues), and it is central to filling the revenue gap.
- ·30.12.2025I had Acasunlimab at 100 price points in my spreadsheet. They are gone now. Remember your own considerations. Happy New Year·30.12.2025Is there anything to suggest that they will deliver a better financial report than the market already expects? It is largely the acquisition of merus that should have the attention here and now, isn't it? Isn't the acquisition completed in Q1? And in that regard, could something emerge that only sees the light of day after closing?
- ·30.12.2025Is there anything to gain here in the short term or is it better to wait to enter? Someone who is well-versed in the case, thanks in advance.·30.12.2025I think it will fall as it did 3 months ago, maybe not quite as sharply. My bet is we will go down and test 1900, but I have nothing but a gut feeling to back it up.·30.12.2025The reason I sold out was that we reached and tested the same level as 3 months ago. So I thought it would probably take a dip down again.
- ·29.12.2025 · MuokattuAcasunlimab is being scrapped. It doesn't come as the world's biggest surprise, considering the entire process, and it became even more likely with the acquisition of Petos. We are still awaiting clarification on GEN1042. Winkel, however, is left somewhat exposed by now, if 1042 also fails and Epco turns out to be the only success from the "own-pipeline" which was otherwise mentioned as promising. Well. Epco itself might be enough to create long-term profit, with Winkel having spoken warmly about there being gold hidden in the books, and that was apparently also mentioned after Epco was manifested.
- ·23.12.2025How long will one have to wait for approval and isn't it overwhelmingly likely that the approval will come?·23.12.2025Does Genmab have any active applications?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt